| NCT ID | NCT03313778 |
| Title | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | yes |
| Sponsors | Moderna Therapeutics |
| Indications | |
| Therapies | |
| Age Groups: | adult senior |